EP4376822A4 - Treatment of cancer with combinations of PARP inhibitors and acylfulvenes - Google Patents

Treatment of cancer with combinations of PARP inhibitors and acylfulvenes

Info

Publication number
EP4376822A4
EP4376822A4 EP22850545.9A EP22850545A EP4376822A4 EP 4376822 A4 EP4376822 A4 EP 4376822A4 EP 22850545 A EP22850545 A EP 22850545A EP 4376822 A4 EP4376822 A4 EP 4376822A4
Authority
EP
European Patent Office
Prior art keywords
acylfulvenes
cancer
combinations
treatment
parp inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22850545.9A
Other languages
German (de)
French (fr)
Other versions
EP4376822A1 (en
Inventor
Aditya Kulkarni
Kishor Bhatia
Jianli Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of EP4376822A1 publication Critical patent/EP4376822A1/en
Publication of EP4376822A4 publication Critical patent/EP4376822A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP22850545.9A 2021-07-29 2022-07-29 Treatment of cancer with combinations of PARP inhibitors and acylfulvenes Pending EP4376822A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227260P 2021-07-29 2021-07-29
US202263365995P 2022-06-07 2022-06-07
PCT/US2022/074314 WO2023010119A1 (en) 2021-07-29 2022-07-29 Treating cancers with combinations of parp inhibitor and acylfulvenes

Publications (2)

Publication Number Publication Date
EP4376822A1 EP4376822A1 (en) 2024-06-05
EP4376822A4 true EP4376822A4 (en) 2025-09-17

Family

ID=85087343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22850545.9A Pending EP4376822A4 (en) 2021-07-29 2022-07-29 Treatment of cancer with combinations of PARP inhibitors and acylfulvenes

Country Status (5)

Country Link
EP (1) EP4376822A4 (en)
JP (1) JP2024528725A (en)
CA (1) CA3227306A1 (en)
MX (1) MX2024001314A (en)
WO (1) WO2023010119A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523864A (en) * 2022-07-15 2025-07-25 ランタン ファルマ インコーポレイテッド Breast cancer and methods for treating PARP-resistant breast cancer
JP2026507923A (en) * 2023-03-09 2026-03-06 ランタン ファルマ インコーポレイテッド Methods for treating renal cell carcinoma or cancer
WO2025043204A2 (en) * 2023-08-23 2025-02-27 Lantern Pharma Inc. Treating liver cancers with hydroxyureamethyl acylfulvene
WO2026064751A1 (en) * 2024-09-23 2026-03-26 Lantern Pharma Inc. Treating pediatric cancers with hydroxyureamethyl acylfulvene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
DK3386546T3 (en) * 2015-12-07 2024-11-25 General Oncology Inc Combination for the effective treatment of metastatic cancer in patients
CN113194934B (en) * 2018-10-14 2025-02-25 蓝腾制药公司 Methods of treating solid tumor cancer using cryptocephalosporin and biomarkers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KULKARNI A ET AL: "LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects", CANCER RESEARCH, vol. 81, no. 13_Suppl, 1 July 2021 (2021-07-01), XP093300530, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-1249 *
See also references of WO2023010119A1 *
UMESH KATHAD ET AL: "A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications", BMC BIOINFORMATICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 22, no. 1, 2 March 2021 (2021-03-02), pages 1 - 23, XP021287233, DOI: 10.1186/S12859-021-04040-8 *

Also Published As

Publication number Publication date
MX2024001314A (en) 2024-04-30
EP4376822A1 (en) 2024-06-05
JP2024528725A (en) 2024-07-30
CA3227306A1 (en) 2023-02-02
WO2023010119A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
EP4326720A4 (en) PARP1 INHIBITORS AND USES THEREOF
EP3600382A4 (en) TREATMENT OF CANCER WITH CAS ENDONUCLEASE COMPLEXES
EP3585817A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP4412716A4 (en) Combinations of KRAS-G12D inhibitors and PI3KA inhibitors and associated treatments
EP4355749A4 (en) TRICYCLIC PARP1 INHIBITORS AND USES THEREOF
EP3612222A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP4125846A4 (en) PYRAZOLYLPROPANMIDE COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF PROSTATE CANCER
EP3592346A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP4232052A4 (en) COMBINATION OF RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
EP4376821A4 (en) Treatment of cancer with combinations of spironolactone and acylfulvenes
EP3528834A4 (en) TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 INHIBITOR
EP3873613A4 (en) MICRORNAS MODIFIED BY 5-HALOGEN-URACIL AND THEIR USE IN THE TREATMENT OF CANCER
EP4412720A4 (en) Combinations of KRAS G12D inhibitors and irinotecan and associated treatments
EP4426688C0 (en) DDR1 and DDR2 inhibitors for the treatment of cancer and fibrotic diseases
IL283899A (en) Combinations of hdm2-p53 interaction inhibitors and bcl2 inhibitor and their use in the treatment of cancer
EP3820492A4 (en) MVPA AND ASSOCIATED USES FOR THE TREATMENT OF CANCER
EP3600329A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP4301356A4 (en) TREATMENT OF BREAST CANCER WITH AMCENESTRATANT AND PALBOCICLIB
EP3877422A4 (en) THERAPEUTIC DOSING SCHEDULES FOR THE TREATMENT OF CANCER WITH ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS
EP4203979C0 (en) TREATMENT OF CANCER AND AUTOIMMUNE AND INFLAMMATORY DISEASES
EP4412613A4 (en) METHODS FOR THE TREATMENT OF CANCER AND TUMORS
EP3532289A4 (en) POLYOXOMETALATE COMPLEXES AND USE IN TREATMENT OF CANCER
EP4247406A4 (en) TREATMENT OF ENPP1 DEFICIENCY AND ABCC6 DEFICIENCY
EP3585398A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP3570837A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF ANDROGEN-FREE CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250819

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/122 20060101AFI20250812BHEP

Ipc: C07C 35/22 20060101ALI20250812BHEP

Ipc: C07C 49/727 20060101ALI20250812BHEP

Ipc: A61P 35/00 20060101ALI20250812BHEP

Ipc: A61K 31/166 20060101ALI20250812BHEP

Ipc: A61K 31/4184 20060101ALI20250812BHEP

Ipc: A61K 31/454 20060101ALI20250812BHEP

Ipc: A61K 31/5025 20060101ALI20250812BHEP

Ipc: A61K 31/55 20060101ALI20250812BHEP

Ipc: A61K 31/502 20060101ALI20250812BHEP

Ipc: A61K 9/00 20060101ALI20250812BHEP

Ipc: A61K 31/337 20060101ALI20250812BHEP

Ipc: A61K 33/243 20190101ALI20250812BHEP